We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00480363
Recruitment Status : Completed
First Posted : May 30, 2007
Last Update Posted : July 31, 2013
Celgene Corporation
Information provided by:
PETHEMA Foundation

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : December 2008
  Study Completion Date : July 2013
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):